ABSTRACT
Effects of the different modes of administration of dichlorotetra-µ-isobutyratodirhenium(ÐÐÐ) Ð (in water solution, liposomes, nanoliposomes and together with cisplatin in the rhenium-platinum system) on the intensity of lipid peroxidation (LP) in blood plasma and the activity of the erythrocyte antioxidant enzymes were investigated on the model of tumor growth. A decrease in the concentration of TBA-active substances caused by dirhenium compounds was shown to be independent of the administration mode and the extent of the tumor growth inhibition. I was four-times more effective in inhibition of the LP burst than any known antioxidant. I induced the increasing activity of erythrocyte superoxide dismutase and decreasing activity of catalase. In vitro experiments with native superoxide dismutase, the interaction of Ð with following activation of the active center of the enzyme was confirmed and the superoxide dismutase activity of Ð was shown, that may contribute to the enhancement of the enzyme activity in vivo. The cluster rhenium compounds may be promising nontoxic potent antioxidants capable of deactivating superoxide radicals.
